Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease by Frederiksen, Kristian S. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Moderate- to high-intensity exercise does not modify cortical -amyloid in Alzheimer's
disease
Frederiksen, Kristian S.; Madsen, Karine; Andersen, Birgitte B.; Beyer, Nina; Garde, Ellen;
Høgh, Peter; Waldemar, Gunhild; Hasselbalch, Steen G.; Law, Ian
Published in:
Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI:
10.1016/j.trci.2019.04.006
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Frederiksen, K. S., Madsen, K., Andersen, B. B., Beyer, N., Garde, E., Høgh, P., ... Law, I. (2019). Moderate- to
high-intensity exercise does not modify cortical -amyloid in Alzheimer's disease. Alzheimer's & Dementia:
Translational Research & Clinical Interventions, 5(1), 208-215. https://doi.org/10.1016/j.trci.2019.04.006
Download date: 06. May. 2020
Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 208-215Featured Article
Moderate- to high-intensity exercise does not modify cortical b-amyloid
in Alzheimer’s diseaseKristian S. Frederiksena,*, Karine Madsenb,c, Birgitte B. Andersena, Nina Beyerd, Ellen Gardee,f,
Peter Høghg,h, Gunhild Waldemara, Steen G. Hasselbalcha, Ian Lawc
aDanish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
bNeurobiology Research Unit, Copenhagen, Denmark
cDepartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
dMusculoskeletal Rehabilitation Research Unit and Institute of Sports Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
eDanish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
fDepartment of Public Health and Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark
gZealand University Hospital, Department of Neurology, Roskilde, Denmark
hDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkAbstract Introduction: Animal models of Alzheimer’s disease show that exercise may modify b-amyloidConflict of interes
*Corresponding au
E-mail address: kr
https://doi.org/10.1016
2352-8737/ 2019 T
license (http://creative(Ab) deposition.We examined the effect of a 16-week exercise intervention on cortical Ab in patients
with mild-to-moderate Alzheimer’s disease.
Methods: Thirty-six patients with Alzheimer’s disease were randomized to either one hour of aero-
bic exercise three times weekly for 16 weeks or usual care. Pre and post intervention, 11Carbon-Pitts-
burgh compound B positron emission tomography was carried out to assess cortical Ab, and
quantified using standardized uptake value rations (SUVRs).
Results: The intervention showed no effect on follow-up SUVRs in a covariance analysis with group
allocation, baseline intervention SUVR, age, sex, and baselineMini–Mental State Examination as pre-
dictors. Change in SUVRs did not correlate with changes in measures of physical or aerobic fitness.
Discussion: The present findings do not support an effect of exercise on Ab. However, the relatively
short intervention period may account for a lack of efficacy. Further studies should test earlier and
longer interventions.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: 11C-PiB-PET; Aerobic exercise; Alzheimer’s disease; b-amyloid; Exercise; Dementia; Intervention; PET;Randomized1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by initially asymptomatic cortical deposition
of the protein b-amyloid (Ab), followed by deposition of
tau and, further downstream, by neurodegeneration and syn-t: None.
thor. Tel.: 145 35456702; Fax: 145 35456922.
istian.steen.frederiksen@regionh.dk
/j.trci.2019.04.006
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).aptic dysfunction, at which time cognitive impairment will
be present or ensue as the disease progresses to dementia [1].
Several lines of evidence have emerged to support the
ability of physical activity to prevent and possibly treat
AD. First, epidemiological studies have found a robust asso-
ciation between physical activity and a reduced risk of
dementia, including AD [2–4]. Second, intervention
studies in mild cognitive impairment [5] and AD [6–9]
indicate that physical exercise improves cognitive function
and other symptoms of AD. Third, animal studies have
shown similar effects [10–12] and further extendedimer’s Association. This is an open access article under the CC BY-NC-ND
Fig. 1. Flowchart of patients in the study.
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pathological changes, such as Ab deposition [10,11,13,14],
tau pathology [15], and hippocampal atrophy [11,16] in
animal models of AD. In humans, most of the studies have
focused on exercise and hippocampal volume [17]. Results
have been divergent, although most studies have shown
a lack of association in both intervention [18–22]
and observational studies [23–28]. There have been
discrepancies in results from observational studies
examining the association between Ab or tau and physical
activity [29–34]. In one study, Ab measured using amyloid
PET, but not cerebrospinal fluid (CSF) Ab levels, was
associated with physical activity levels [29]. In general, a
relatively high concordance regarding amyloid positivity as-
sessed by CSF- and PET-derived measures has been re-
ported, although correlations within positive and negative
groups are low between the two measures [35]. Hence, these
two measures of Ab may not be interchangeable. Amyloid
PET is a measure of brain fibrillary Ab [36], whereas CSF
Ab may instead reflect soluble species of Ab and, as such,
is only an indirect measure of fibrillary Ab [37]. CSF Ab
has also been reported to be sensitive to variations in Ab pre-
cursor protein processing and Ab production [38,39], and
CSF Ab concentrations may change earlier in the disease
process [40]. These observations indicate that amyloid
PET and CSF measures may reflect different aspects of Ab
biology. It may be further speculated that physical activity
affects specific aspects of Ab biology, which is best captured
by one or the other biomarker (e.g., fibrillar vs. soluble Ab),
reflected in the apparently discrepant effect of physical
activity on PET- versus CSF-assessed Ab levels [29]. In a
previous study using a subsample from the same randomized
controlled trial (RCT) as in the present study, 16 weeks of
aerobic exercise did not affect the CSF levels of the AD
biomarkers, including Ab [41]. In the present study, we
examined whether aerobic exercise in a substudy population
from the same RCT modulated cortical Ab in patients
with mild AD assessed using a different modality (11Car-
bon-Pittsburgh compound B positron emission tomography
[11C-PiB-PET]). To our knowledge, this is the first study
to assess the effects of an aerobic exercise intervention on
Ab assessed by PET imaging.2. Methods
2.1. Study design and population
The present study reports the results of an imaging sub-
study from the Preserving Cognition, Quality of Life, Phys-
ical Health and Functional Ability in Alzheimer’s Disease:
The Effect of Physical Exercise (ADEX) study, a multi-
center, single-blinded RCT of physical exercise in patients
with mild AD. Details of the rationale and study design
can be found elsewhere [42], as well as the main findings
[7,43]. The intervention comprised 16 weeks of moderate-
to high-intensity aerobic exercise three times weekly forone hour. The exercise sessions were conducted in groups
supervised by a trained physiotherapist. The first four weeks
were a ramp-up period in which participants were familiar-
ized with the exercise equipment and emphasis was put on
strength exercises. This was done to avoid injuries because
initial piloting indicated injuries as a potential problem
[44]. For the main study, 200 participants from eight centers
were recruited and underwent clinical assessment of cogni-
tive function, activities of daily living, physical function,
aerobic fitness, neuropsychiatric symptoms at baseline,
and took part in a 16-week follow-up. All assessments
were performed by assessors blinded to group allocation. In-
clusion criteria for the main study were the following: (1)
AD according to NINCDS-ADRDA Alzheimer’s Criteria
and DSM-IV codes; (2) between 50 and 90 years of age;
(3) a Mini–Mental State Examination score of more than
19; (4) at least three months of stable doses if receiving anti-
dementia medication or mood-stabilizing medication; and
(5) informed consent. Exclusion criteria included the
following: (1) severe psychiatric illness; (2) alcohol or
drug abuse within the last two years; (3) participation in
aerobic exercise (moderate to high intensity) more than
twice weekly on a regular basis; and (4) any medical condi-
tion precluding participation in the exercise program (e.g.,
severe neurological or medical illness and presence of
several cardiovascular risk factors). Further inclusion
criteria for the imaging substudy included the absence of
contraindications for undergoing magnetic resonance imag-
ing (MRI). All participants recruited at two (Rigshospitalet,
Roskilde) of the eight centers were asked to participate in the
imaging substudy. Theywere also asked to undergoMRI and
PETat baseline and at 16-week follow-up. A total of 72 par-
ticipants were recruited at the two centers, 54 of whom were
included in the imaging substudy and randomized. Five par-
ticipants dropped out during the intervention (dropout rate
9.3 %), and the quality of scans for an additional 13 was
insufficient to enable analysis, leaving a sample of 36 partic-
ipants (20 intervention group; 16 usual care) for the final
analysis (see Fig. 1). The ADEX trial was approved by the
Committees of Biomedical Research Ethics for the Capital
K.S. Frederiksen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 208-215210Region (protocol no.: H-3-2011-128) and by the Danish
Data Protection Agency (file no.: 30-0718). The trial was
registered at ClinicalTrials.gov (identifier: NCT01681602)
on September 10, 2012.
2.2. Cognitive tests
Cognitive assessment was carried out using Mini–Mental
State Examination for global cognitive impairment [45].
2.3. Activities of Daily Living scale
For assessment of activities of daily living function the
Alzheimer’s Disease Cooperative Study–Activities of Daily
Living scale [46] was used.
2.4. Measures of aerobic fitness and physical function
Several different tests were used to assess aerobic fitness
and physical function. The 6-minute Astrand Cycle Ergom-
eter test (Monark Ergomedic 839E; Monark Exercise AB,
Sweden) was used to estimate the maximal oxygen uptake
based on workload and average heart rate (HR) during the
last minute of the 6-minute cycle test, corrected for age
and body weight. Peak oxygen uptake (VO2max) was used
as a measure of aerobic fitness [47]. For the Timed Up and
Go test (TUG), which was used to assess general mobility,
the amount of time it took participants to rise from a chair,
walk 3 meters as quickly and safely as possible, turn around,
walk back, and sit down were measured [48]. For assessment
of lower extremity strength and endurance, the 30-s sit-
to-stand test (STS) was used and measures the number of
stands completed with the arms folded across the chest
within 30 seconds [49]. Walking endurance was assessed
with a 400-m walk test. The participants were instructed to
walk as quickly as possible without support or sitting
down, although standing breaks of up to one minute were
allowed [50]. Finally, usual gait speed (m/s) was assessed
with a 10-m walk test [51].
2.5. Physical activity
Level of physical activity at baseline was assessed using
the Physical Activity Scale for the Elderly [52], which was
filled out by the patient’s caregiver.
2.6. Exercise load (attendance and intensity)
To assess attendance and intensity of training, the physio-
therapist instructor at each center completed a training log.
Attendance ratio was defined as the number of attended ex-
ercise sessions over total number of sessions. Exercise inten-
sity was based on the per-session average HR recorded using
continuous monitoring during exercise (including rest pe-
riods). Average HR for all sessions was calculated, with in-
tensity defined as average HR over maximum expected HR
(220 minus participant age). To obtain total exercise load,
measures for attendance ratio and intensity were multiplied.2.7. Magnetic resonance imaging
Baseline and follow-up MRI scans were performed on a
3 Tesla Siemens Trio scanner. Both baseline and follow-up
scans were acquired on the same scanner. For the purpose
of coregistration to the PET image, a T1-weighed
magnetization-prepared rapid gradient echo sequence (TE
3.04 ms, TR 1550 ms, FoV read 256 mm, FoV phase
100%, 192 slices) was used.
The T1-weighted MRI scans were segmented into gray
matter, white matter, and CSF using Statistical Parametric
Mapping 5 (Wellcome Department of Cognitive Neurology,
London, UK). Regions of interest were automatically delin-
eated on each subject’s MRI in a user-independent fashion
with the PVElab software package (Neurobiology Research
Unit, Rigshospitalet, Copenhagen, Denmark) [53].
2.8. PET imaging
PET images were acquired using either a Siemens Bio-
graph 40 or Biograph TruePoint 64 PET/CT scanner
(Siemens Healthcare, Erlangen, Germany) and the tracer
11C-PiB-PET, which binds with affinity to Ab. Both base-
line and follow-up scans were acquired on the same scanner.
11C-PIB was administered as a bolus with a mean activity of
421 MBq (183-754 MBq) per injection, with image acquisi-
tion 40–70 minutes after injection as 6! 5-minute frames.
The time window 40- to 70-minute postinjection was used
because it provides stability and an effective contrast be-
tween healthy subjects and patients with AD [54].
Default random, scatter, and dead time correction and
low-dose CT-based attenuation correction were applied
(120 kVp, 40 mA) for all images. Image reconstruction
was performed using a 2D ordered-subsets expectation
maximization algorithm with 6 iterations and 16 subsets
and filtered with a 5-mm (full-width, half-maximum)
gaussian filter.
2.9. Image analysis
PET images were coregistered to MRI images (Statistical
Parametric Mapping 5; Wellcome Department of Cognitive
Neurology) and evaluated by visual inspection by the same
reader trained and blinded to time of scan and group alloca-
tion. Mean voxel movement between frames (5–10 minutes)
was measured using AIR 5.2.5 (LONI, UCLA, CA, USA)
[55]. When movement exceeded 3 mm, movement correc-
tion was applied. The regional PET standardized uptake
value (SUV) was measured by summing the data of consec-
utive time frames from regional gray matter voxels. The
cerebellar gray matter (excluding vermis) was used as the
reference region for normalization [56,57]. The global
11C-PiB binding was expressed as the mean standardized
uptake value ratio (SUVR) of six regions: lateral temporal
cortex (including the superior, medial, and inferior lateral
gyri), posterior cingulated gyrus, anterior cingulated gyrus,
precuneus, parietal cortex, and lateral prefrontal cortex
Table 1
Baseline demographics and clinical variables
Variables
Intervention
(n 5 20)
Usual care
(n 5 16) P value
Age, years, mean (SD) 68.7 (7.6) 70.4 (7.4) 0.43
Sex distribution (female/male) 10/10 8/8 1
Baseline MMSE, mean (SD) 25.5 (3.0) 25.8 (2.7) 0.87
Baseline ADCS-ADL,
baseline mean (SD)
68.1 (10.0) 68.2 (7.5) 0.76
Baseline PASE, mean (SD)* 83.6 (43.1) 95.7 (39.0) 0.26
Baseline estimated VO2max
y
(mL/kg/min)
24.7 (6.4) 25.7 (6.4) 0.49
Baseline SUVRz 2.35 (0.37) 2.07 (0.46) 0.049
NOTE. P values are for unpaired Student’s t-test and the c2 test
comparing the two groups.
Abbreviations: ADCS-ADL, Alzheimer’s Disease Cooperative Study–
Activities of Daily Living scale; MMSE, Mini–Mental State Examination;
PASE, Physical Activity Scale for the Elderly; SD, standard deviation;
SUVR, standardized uptake value ratio.
*PASE was filled out by the caregiver.
yn 5 13 for usual care and n 5 18 for the intervention.
zMean SUVR across six regions. See 2.9 Image Analysis for details
regarding anatomical regions.
Fig. 2. Change from baseline in standardized uptake value ratios. The graph
shows mean and standard deviation of standardized uptake value ratios for
both groups at baseline and at the 16-week follow-up for six regions: lateral
temporal cortex, posterior cingulated gyrus, anterior cingulated gyrus, pre-
cuneus, parietal cortex, and lateral prefrontal cortex.
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previously described [58]. Furthermore, a voxel-based anal-
ysis was carried out to further confirm any findings from the
initial analysis. Supplementary Material contains details
about this. Analysis of the PET images was carried out
blinded to the group allocation of participants.2.10. Statistical analysis
Student’s unpaired-samples t-test and the c2 test were
used to compare baseline demographic and clinical charac-
teristics between groups. For analysis of the effects of the
intervention on cortical Ab, we performed analysis of
covariance with SUVRs at follow-up as dependent variables
and group allocation, baseline SUVR, age, baseline
Mini–Mental State Examination, and sex as covariates as
independent variables. Analysis of covariance was chosen
because it has been shown to increase power in the analysis
of results from RCTs [59]. To test the relationship between
improvement in aerobic fitness and change in cortical Ab,
Spearman’s rank correlation between change in estimated
VO2max and change in SUVR was calculated. Similarly,
Spearman’s rank correlation was used to assess the relation-
ship between change in physical fitness and performance as
measured by changes in the TUG, STS, 10-m and 400-m
walk tests, as well as a change in SUVR. Finally, correlation
between exercise load and change in SUVR was assessed.
All correlations were assessed in the exercise group only.
Student’s paired-samples t-test was used to assess change
from baseline to follow-up within the exercise group. This
was carried out to assess whether the intervention had
improved the aerobic fitness and physical function of the
participants, as has been shown in the whole study popula-
tion [43].Statistical significance was set at P , .05 (two-tailed).
Statistical analysis was carried out using Intercooled Stata
9.2 for Macintosh (Stata Corporation, USA).3. Results
3.1. Baseline characteristics
The final analysis included 36 subjects, 20 of whom were
randomized to the intervention and 16 to usual care. There
were no significant differences in baseline characteristics,
except for baseline 11C-PiB binding, where subjects in the
intervention group had a significantly higher level of binding
(P 5 .049) (see Table 1). One patient from the intervention
group (SUVR 1.16) and one patient from the usual care
group (1.20) had a mean SUVR of ,1.6 indicative of a
PiB-negative scan. All analyses were also carried out
excluding those two patients without changing the results.3.2. Effect of the intervention on cortical 11C-PiB binding
There was no significant difference within the two groups
in SUVRs in the predefined region of interest from baseline
to follow-up [intervention group—baseline mean (SD): 2.35
(0.37); follow-up: 2.37 (0.37) P 5 .46; usual care group—
baseline: 2.07 (0.46); follow-up: 2.04 (0.47) P 5 .68]
(Fig. 2). Similarly, there were no significant effects from
any of the voxel-wise statistical parametric mapping ana-
lyses, even after lowering the statistical threshold.3.3. Change from baseline to follow-up physical measures
Participants in the intervention group improved with
regard to estimated VO2max (P , .01) and the 400-m walk.
Table 2
Measures of physical function, aerobic fitness, and exercise load
Variables
Usual care group Intervention group
Baseline
Change
from
baseline Baseline
Change
from
baseline
Timed Up and
Go test (sec)
6.3
(61.1)
20.1
(60.6)
5.7
(61.3)
20.5
(61.5)
Sit-to-stand test* 16.5 (2) 1
(1.75)y
13.5
(4.75)
1
(2.75)
Estimated VO2max
(mL/kg/min)
26.2
(66.4)
20.8
(62.5)
23.8
(66.5)
2.3
(63.5)z
400-meter walk
test (sec)
278.5
(654)
2.3
(615.3)
270.7
(648.9)
217.0
(625.6)z
NOTE. Results are reported as mean (standard deviation), except for the
sit-to-stand test and exercise load, which are reported as median (interquar-
tile range). Negative change scores indicate improvements for the Timed Up
and Go and 400-meter walk tests and deterioration for the sit-to-stand and
estimated VO2max.
*Reported as number of rises in the allotted time.
yP , .05.
zP , .01.
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score increased (Table 2), indicating improved lower
leg strength.
3.4. Correlations with change in physical function and
aerobic capacity
There were no significant correlations between changes
in the TUG, STS, 10-m and 400-m walk tests, and change
in SUVR. Furthermore, exercise load did not correlate
with change in SUVR.4. Discussion
To our knowledge, this is the first human study to evaluate
the effects of physical exercise on Ab using amyloid PET. In
this single-blinded RCT, we tested whether a 16-week inter-
vention with moderate- to high-intensity aerobic exercise
was able to modify the level of cortical Ab in patients with
mild AD. Our findings were twofold. First, and regarding
the main objective of the study, we did not find an effect
of the exercise intervention on cortical Ab compared with
usual care. Second, we did not find that change from baseline
to follow-up in cortical Ab and measures of aerobic physical
fitness correlated.
As outlined previously, different lines of evidence
demonstrate the positive effect of exercise on cognitive
function and risk of dementia [10–16,18–34]. However,
the biological mechanisms by which this effect may be
mediated remain to be clarified. Various mechanisms,
pathways, and molecular targets have been proposed and
explored in animal studies [15,60–66], but the number of
human studies is small. Several animal studies have
endeavored to determine the possible mechanisms by
which exercise might reduce Ab levels. Nigam et al. [60]found that exercise enhanced the activity of a-secretase, an
enzyme that initiates the nonamyloidogenic processing
pathways by which the amyloid precursor protein is cleaved
in its intramembrane domain. This releases a large soluble
protein, which may have neuroprotective properties [67],
and also, importantly, hinders the production of Ab because
the cleavage site is in the amino acid sequence of the Ab pro-
tein. Conversely, in the amyloidogenic pathway, the amyloid
precursor protein is cleaved by b-secretase and g-secretase,
releasing the Ab protein. In another study that also uses an
animal model of AD, exercise was found to downregulate
g-secretase [68], indicating that exercise may both upregu-
late the nonamyloidogenic pathway and downregulate the
amyloidogenic pathway. Another possibility is that clear-
ance of Ab is increased by exercise [13,69]. From a
theoretical point of view, it may be speculated that an
increased clearance of Ab may be more relevant to the
patients in the present study because deposition of Ab in
sporadic AD is associated with decreased clearance [70].
On the other hand, this does not rule out a positive effect
of a downregulation of Ab production in sporadic AD.
Other aspects of Ab biology may play a role in the nega-
tive findings of the present study such as a selective effect of
exercise on soluble species of Ab over Ab plaques, as indi-
cated by the findings in an observational study [29]. Howev-
er, in another subpopulation from the ADEX study, exercise
also failed to affect the level of Ab in CSF, which may pri-
marily reflect soluble forms of Ab [37]. Furthermore, animal
studies have demonstrated a direct effect of exercise on num-
ber of plaques [63] and plaque formation [71]. However, the
issue of an effect on soluble versus plaque forms of Ab ties
directly into an additional perspective, namely, the timing of
the intervention. Across animal studies, there seems to be a
trend toward exercise being more effective in reducing Ab
and plaque formation, the earlier in the disease process it
is initiated [72]. This also coincides with the pathophysio-
logical process when soluble Ab, but not plaques, may pre-
dominate. A move toward earlier stages of AD pathology
with regard to exercise interventions would mirror the trend
in studies of, e.g., monoclonal antibodies directed toward Ab
[73,74]. To our knowledge, at least one exercise study is
underway that is testing this hypothesis (ClinicalTrials.
gov, identifier NCT02000583).
Another factor that is likely to play a role in the present
findings is the length of the intervention, which was rela-
tively short when considering that AD pathology may build
up over years. In recent years, phase II and III trials have
tested several monoclonal antibodies directed toward Ab
and drugs modulating the activity of the aforementioned sec-
retases that have demonstrated an ability to reduce cortical
Ab, although none of them have reached clinical endpoints
in phase III trials. These studies were performed over a
period of one to two years [75], which may indicate the
length of time that a therapy must be maintained to affect
cortical Ab. Whether this is transferable to exercise remains
speculative. In animal models of AD, the length of
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brief 10-day intervention using wheel running led to a
decrease in Ab and APP mRNA, indicating target engage-
ment, although the number of plaques did not decrease
[76]. The shortest intervention tested in animal models that
was able to modify Ab lasted around three months [72].
The intensity of the exercise intervention may also affect
the ability of the intervention to modify Ab. In the present
study, where the intensity was moderate to high, we were
able to demonstrate a significant improvement in the inter-
vention group for estimated VO2max. This is in accordance
with the findings in the entire ADEX study cohort [43].
Other studies in patients with dementia have, in general,
used lower-intensity exercise [6,77–80]. From a clinical
point of view, it may not be feasible to carry out an
exercise program of higher intensity in this patient group.
Moore et al. [13], who divided a group of transgenic mice
into sedentary, low-intensity, and high-intensity exercise
groups, found a dose response with regard to reducing pla-
que formation. Two conclusions may be gleaned from these
findings (1) that there is not necessarily a level of intensity
below which exercise does not affect Ab and (2) that more
is better in relation to intensity. The fact that we were able
to detect an improvement in estimated VO2max also indicates
that the program was sufficient and that if modulation of Ab
is mediated through an improvement in aerobic fitness, this
was not the cause of the negative findings.
The present study has several weaknesses. As discussed,
the duration of the intervention may have led to negative
findings and it is not improbable that an intervention over
a longer period may have had an effect on Ab. Moreover,
the study population was relatively small partly because of
dropout and insufficient quality of the acquired scans.
This study also has several strengths. First, it is well
designed and has a well-characterized patient group, both
regarding certainty of diagnosis and the variables included,
i.e., demographics and clinical data collected from the pa-
tients. Second, the differing SUVR values between the two
groups cannot be interpreted as a failure of the randomiza-
tion process. Moreover, any baseline difference was ac-
counted for in the statistical analysis by including baseline
values as a covariate. In addition, we were able to monitor
closely whether participants were present at training ses-
sions, whereas pulse watches allowed us to accurately record
exercise intensity. Finally, the exercise program was super-
vised by trained physiotherapists and performed in small
groups, which may have improved adherence. This approach
also allowed us to offer relatively high-intensity exercise to a
comparatively fragile patient group.
In conclusion, the present findings in this exercise inter-
vention study do not support previous findings from, pri-
marily, animal studies of an effect of exercise on Ab,
which is in line with previous findings in the ADEX study
on CSF levels of Ab. However, the findings also do not
definitively rule out an effect. Future studies should focus
on longer intervention studies, in patients in earlier stagesof AD pathology, e.g., patients with preclinical AD or pa-
tients without symptoms but positive AD biomarkers. In
addition to exploring alternative pathways, future studies
should aim to assess Ab in CSF and by amyloid PET, as
well as tau markers, to further shed light on how exercise
may modulate the amyloid cascade.
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1. Systematic Review:We searched for relevant articles
in PubMed on the topic of physical exercise and its
effect on Alzheimer’s disease pathology. A large
body of animal studies has found that physical activ-
ity may modify b-amyloid pathology, but studies in
humans are lacking.
2. Interpretation: Our findings do not support a disease-
modifying effect of physical exercise as assessed by
the effect on b-amyloid in patients with Alzheimer’s
disease.
3. Future directions: Future studies are needed to
further assess the effects of physical exercise as a
possible disease-modifying strategy, specifically,
ones examining longer interventions and in-
terventions in earlier stages of the disease. Moreover,
other components of Alzheimer’s disease patho-
physiology, such as tau deposition, may be differ-
entially affected and should also be explored.References
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